A few open pilot studies of SGLT2 inhibitor in NAFLD patients are ongoing in the western countries (NCT02696941) or Asia (NCT02875821, NCT02964715). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.